UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

Bristol-Myers Squibb (BMY) shares rose early Friday as the biopharmaceutical company obtained approval from the US Food and Drug Administration for its Cobenfy drug to treat schizophrenia in adults.

PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...

The pound was quoted at USD1.3366 early on Friday in London, compared to USD1.3412 at the equities close on Thursday. The euro stood at USD1.1135, lower against USDUSD1.1179. Against the yen, the ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...

While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites ...

Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical ...

SAN DIEGO – In a recent transaction on September 23, Andrew Reardon, the Chief Legal Officer (CLO) and Secretary of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), sold shares of the company's stock, ...

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for ...

In a federal tax court petition, Abbott rejects numerous "arbitrary, capricious and unreasonable" determinations the IRS made ...

Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To ...